- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT02706223
Testing and Treating Hepatitis C in Community Pharmacies (SuperDOT-C)
A Cluster Randomised Trial of Pharmacy Led HCV Therapy Versus Conventional Treatment Pathways for HCV Positive Patients Receiving Daily OST in Pharmacies in Health Boards Within NHS Scotland
Hepatitis C Virus, (HCV), infection is a major health concern in the UK with up to 0.7% of the population infected. At best, 25% of those infected will clear the infection spontaneously, though for those who develop a chronic infection, they may go onto to develop liver cirrhosis or liver cancers.
The standard of care within the NHS is that patients with a history of intravenous drug use or those currently on methadone are at high risk of having HCV infection and should be offered HCV testing. Once diagnosed they can be referred to nurse led treatment pathways. Less than 10% of the methadone users are even tested for HCV and of them fewer than 20% go onto treatment regimens that successfully clear the infection despite regular interactions with heath care staff.
Pharmacists who have daily interactions with patients receiving methadone are ideally placed to deliver anti HCV therapy as they have daily contact with this client group and are well placed to advise on the drug therapy.
The SuperDOT C study will examine the impact of pharmacy led Directly Observed Therapy (DOT) for HCV treatment in patients attending Community Pharmacies in participating Health Boards within NHS Scotland. The impact of this approach will be compared with those referred to standard care pathways on how well participants clear their HCV infection.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Aberdeen, Verenigd Koninkrijk, AB25 2ZN
- NHS Grampian
-
Dundee, Verenigd Koninkrijk, DD1 9SY
- NHS Tayside
-
Glasgow, Verenigd Koninkrijk, G$ 0SF
- NHS Greater Glasgow and Clyde
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- HCV PCR positive,
- Stable OST dose for greater than 12 weeks prior to study enrolment
Exclusion Criteria:
- Evidence of current or previous decompensated liver disease,
- Currently receiving HCV eradication treatment
- HIV infection,
- HBsAg positive with detectable HBV DNA,
- Pregnancy
- Cirrhosis or high fibrosis score
- Genotype deemed unsuitable for treatment with available study drugs
- Unable or unwilling to provide informed consent
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Experimenteel: Pharmacist Led
This arm involved subjects following pathway of care and treatment delivery delivered by community pharmacists
|
Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
|
Experimenteel: Nurse Led
This arm involved subjects following the conventional pathway of care and treatment delivery delivered by specialist secondary care nurses
|
Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Rate of Sustained Viral Response at 12 weeks, (SVR12), in pharmacy pathway compared with that of the current treatment pathway 12 weeks after completion of HCV therapy
Tijdsspanne: 12 week SVR, (12 weeks post completion of HCV treatment)
|
Blood test result; PCR - based measurement of levels of hepatitis C virus.
|
12 week SVR, (12 weeks post completion of HCV treatment)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Cost effectiveness of the pharmacist pathway as compared with the conventional care pathway
Tijdsspanne: Span of study ie 24 months
|
Health economics analysis
|
Span of study ie 24 months
|
To determine whether the Pharmacist-led pathway compared with the Conventional Pathway leads to more people on OST being tested and initiating treatment
Tijdsspanne: Span of study ie 24 months
|
Comparison of rate of HCV testing rates in pharmacist pathway compared with current pathway
|
Span of study ie 24 months
|
To explore whether adherence and persistence to HCV therapy in the pharmacy setting is at least similar to that in the Conventional pathway
Tijdsspanne: Span of study ie 24 months
|
Comparison of compliance rates of antiviral medications between pharmacist and conventional pathway.
|
Span of study ie 24 months
|
To compare the acceptability of the Pharmacist-led pathway versus the conventional treatment pathway for OST clients
Tijdsspanne: Span of study ie 24 months
|
Compare the acceptability of the pharmacist pathway as compare to conventional pathway of care
|
Span of study ie 24 months
|
To measure re-infection rate at 1 year after end of treatment in patients with SVR
Tijdsspanne: Span of study ie 24 months
|
Comparison of the rate of reinfections with HCV between pharmacist and conventional pathways
|
Span of study ie 24 months
|
To compare the number of patients who drop out of the study between the two pathways
Tijdsspanne: Span of study ie 24 months
|
Comparison of subject drop out rates between pharmacist and conventional pathways
|
Span of study ie 24 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: John F Dillon, MD, University of Dundee
Publicaties en nuttige links
Algemene publicaties
- Radley A, de Bruin M, Inglis SK, Donnan PT, Hapca A, Barclay ST, Fraser A, Dillon JF. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial. Lancet Gastroenterol Hepatol. 2020 Sep;5(9):809-818. doi: 10.1016/S2468-1253(20)30120-5. Epub 2020 Jun 8.
- Hickman M, Dillon JF, Elliott L, De Angelis D, Vickerman P, Foster G, Donnan P, Eriksen A, Flowers P, Goldberg D, Hollingworth W, Ijaz S, Liddell D, Mandal S, Martin N, Beer LJZ, Drysdale K, Fraser H, Glass R, Graham L, Gunson RN, Hamilton E, Harris H, Harris M, Harris R, Heinsbroek E, Hope V, Horwood J, Inglis SK, Innes H, Lane A, Meadows J, McAuley A, Metcalfe C, Migchelsen S, Murray A, Myring G, Palmateer NE, Presanis A, Radley A, Ramsay M, Samartsidis P, Simmons R, Sinka K, Vojt G, Ward Z, Whiteley D, Yeung A, Hutchinson SJ. Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol). BMJ Open. 2019 Sep 24;9(9):e029538. doi: 10.1136/bmjopen-2019-029538.
- Radley A, de Bruin M, Inglis SK, Donnan PT, Dillon JF. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial. BMJ Open. 2018 Dec 14;8(12):e021443. doi: 10.1136/bmjopen-2017-021443.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 2014GA07
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Hepatitis C
-
Tripep ABInovio PharmaceuticalsOnbekendChronische hepatitis C-virusinfectieZweden
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsIngetrokkenChronische hepatitis C-virusinfectieIsraël
-
Hadassah Medical OrganizationOnbekendChronische hepatitis C-virusinfectieIsraël
-
Trek Therapeutics, PBCVoltooidChronische Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV) | Hepatitis C virale infectieVerenigde Staten, Nieuw-Zeeland
-
Trek Therapeutics, PBCVoltooidChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 4 | Hepatitis C virale infectieVerenigde Staten
-
AbbVieVoltooidHepatitis C-virus | Chronisch hepatitis C-virus
-
Beni-Suef UniversityVoltooidChronische hepatitis C-virusinfectieEgypte
-
AbbVieVoltooidChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis C Genotype 1a
-
University Health Network, TorontoVoltooidChronische hepatitis C-infectieCanada
-
AbbVie (prior sponsor, Abbott)VoltooidChronische Hepatitis C | Hepatitis C Genotype 1 | Hepatitis C (HCV)Verenigde Staten, Australië, Canada, Frankrijk, Duitsland, Nieuw-Zeeland, Puerto Rico, Spanje, Verenigd Koninkrijk
Klinische onderzoeken op Pharmacist Led
-
Universidade Estadual de LondrinaVoltooid
-
VA Office of Research and DevelopmentActief, niet wervendTraumatische hersenschade | Post-traumatische stress-stoornisVerenigde Staten
-
University of Nove de JulhoOnbekendTemporomandibulaire stoornisBrazilië
-
Federal University of Health Science of Porto AlegreVoltooidVeroudering | Rimpels
-
New York Institute of TechnologyWervingPijn, chronisch | Ehlers-Danlos-syndroomVerenigde Staten
-
University of BergenGlamoxVoltooidSlaap | Slaaptekort | Ploegendienstgerelateerde slaapstoornissenNoorwegen
-
Erebouni Medical CenterWervingNeonatale hyperbilirubinemie | Geelzucht, neonataalArmenië
-
Kaohsiung Medical UniversityVoltooidSlaapstoornis | Dementie | Milde cognitieve stoornis | FototherapieTaiwan
-
University of Nove de JulhoOnbekend